Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial

ROCKET AF Investigators; Daniel E Singer; Anne S Hellkamp; Jonathan P Piccini; Kenneth W Mahaffey; Yuliya Lokhnygina; Guohua Pan; Jonathan L Halperin; Richard C Becker; Günter Breithardt; Graeme J Hankey; Werner Hacke; Christopher C Nessel; Manesh R Patel; Robert M Califf; Keith A A Fox

doi:10.1161/JAHA.112.000067

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial

ROCKET AF Investigators, Daniel E Singer, Anne S Hellkamp, Jonathan P Piccini, Kenneth W Mahaffey, Yuliya Lokhnygina, Guohua Pan, Jonathan L Halperin, Richard C Becker, Günter Breithardt, Graeme J Hankey, Werner Hacke, Christopher C Nessel, Manesh R Patel, Robert M Califf, Keith A A Fox

Research output: Contribution to journal › Article › peer-review

Abstract

Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.

Original language	English
Pages (from-to)	e000067
Journal	Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease
Volume	2
Issue number	1
DOIs	https://doi.org/10.1161/JAHA.112.000067
Publication status	Published - Feb 2013

Access to Document

10.1161/JAHA.112.000067

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy
© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley‐Blackwell. This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Final published version, 722 KBLicence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

http://jaha.ahajournals.org/content/2/1/e000067.full

Cite this

ROCKET AF Investigators, Singer, D. E., Hellkamp, A. S., Piccini, J. P., Mahaffey, K. W., Lokhnygina, Y., Pan, G., Halperin, J. L., Becker, R. C., Breithardt, G., Hankey, G. J., Hacke, W., Nessel, C. C., Patel, M. R., Califf, R. M., & Fox, K. A. A. (2013). Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, 2(1), e000067. https://doi.org/10.1161/JAHA.112.000067

ROCKET AF Investigators ; Singer, Daniel E ; Hellkamp, Anne S ; Piccini, Jonathan P ; Mahaffey, Kenneth W ; Lokhnygina, Yuliya ; Pan, Guohua ; Halperin, Jonathan L ; Becker, Richard C ; Breithardt, Günter ; Hankey, Graeme J ; Hacke, Werner ; Nessel, Christopher C ; Patel, Manesh R ; Califf, Robert M ; Fox, Keith A A. / Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy : data from the ROCKET AF clinical trial. In: Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease. 2013 ; Vol. 2, No. 1. pp. e000067.

@article{a2de7da41db04d65ac387b51a9f96728,

title = "Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial",

abstract = "Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.",

author = "{ROCKET AF Investigators} and Singer, {Daniel E} and Hellkamp, {Anne S} and Piccini, {Jonathan P} and Mahaffey, {Kenneth W} and Yuliya Lokhnygina and Guohua Pan and Halperin, {Jonathan L} and Becker, {Richard C} and G{\"u}nter Breithardt and Hankey, {Graeme J} and Werner Hacke and Nessel, {Christopher C} and Patel, {Manesh R} and Califf, {Robert M} and Fox, {Keith A A}",

year = "2013",

month = feb,

doi = "10.1161/JAHA.112.000067",

language = "English",

volume = "2",

pages = "e000067",

journal = "Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease",

issn = "2047-9980",

publisher = "Wiley Open Access",

number = "1",

}

ROCKET AF Investigators, Singer, DE, Hellkamp, AS, Piccini, JP, Mahaffey, KW, Lokhnygina, Y, Pan, G, Halperin, JL, Becker, RC, Breithardt, G, Hankey, GJ, Hacke, W, Nessel, CC, Patel, MR, Califf, RM & Fox, KAA 2013, 'Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial', Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, vol. 2, no. 1, pp. e000067. https://doi.org/10.1161/JAHA.112.000067

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy : data from the ROCKET AF clinical trial. / ROCKET AF Investigators; Singer, Daniel E; Hellkamp, Anne S; Piccini, Jonathan P; Mahaffey, Kenneth W; Lokhnygina, Yuliya; Pan, Guohua; Halperin, Jonathan L; Becker, Richard C; Breithardt, Günter; Hankey, Graeme J; Hacke, Werner; Nessel, Christopher C; Patel, Manesh R; Califf, Robert M; Fox, Keith A A.

In: Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease, Vol. 2, No. 1, 02.2013, p. e000067.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy

T2 - data from the ROCKET AF clinical trial

AU - ROCKET AF Investigators

AU - Singer, Daniel E

AU - Hellkamp, Anne S

AU - Piccini, Jonathan P

AU - Mahaffey, Kenneth W

AU - Lokhnygina, Yuliya

AU - Pan, Guohua

AU - Halperin, Jonathan L

AU - Becker, Richard C

AU - Breithardt, Günter

AU - Hankey, Graeme J

AU - Hacke, Werner

AU - Nessel, Christopher C

AU - Patel, Manesh R

AU - Califf, Robert M

AU - Fox, Keith A A

PY - 2013/2

Y1 - 2013/2

N2 - Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.

AB - Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial.

U2 - 10.1161/JAHA.112.000067

DO - 10.1161/JAHA.112.000067

M3 - Article

C2 - 23525418

VL - 2

SP - e000067

JO - Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease

JF - Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease

SN - 2047-9980

IS - 1

ER -

ROCKET AF Investigators, Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease. 2013 Feb;2(1):e000067. https://doi.org/10.1161/JAHA.112.000067

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial

Abstract

Access to Document

Fingerprint

Cite this